Daily FNArena News - Australia

A softer-than-usual start to 2013 has put the spotlight on InvoCare’s valuation. Brokers find it expensive but justifiable on a long-term view.

A site tour of the GLNG project has prompted analysts to call Santos undervalued by a sceptical market.

Weekly update on recommendation, target price, and earnings forecast changes.

A wrap of the day’s activity on the Australian stock market.

A wrap of the day’s activity on the Australian stock market.

Myer’s March quarter sales growth was soft and it’s likely more than just seasonal factors that are making times challenging.

Banks are now all about yield, but on low earnings growth and already elevated payouts, do brokers see any value left following the bank reporting season?

Cochlear implant companies will launch new products at the EU conference this week. Brokers flag just how much of Cochlear’s market share is under pressure.

As another mining services company downgrades earnings forecasts, brokers scout for mitigating factors. There are a few for Boart Longyear.

A wrap of the day’s activity on the Australian stock market.